Comparison of Efficacy and Toxicity of First Line Chemotherapy with or without Epirubicin for Patients with Advanced Stage Soft Tissue Sarcoma

Abstract

Response was assessed using RECIST criteria. The Kaplan-Meier method was used to estimate progress free survival (PFS). Results: According to RECIST criteria , patients in group treated by chemotherapy without epirubicin, the objective response (OR) ratio was 6.5 % (CR0%+PR6.5%). Disease control rate (DCR=CR+PR+SD) was 25.8% with a median follow-up of 14.6 months, including 2 patients achieving a partial response (PR 6.5%) and a stable response (SD 19.4%) in 6. In group B with epirubicin based regimens, no patient had complete response, PR (28 %) was observed in 7 and SD (24 %) in 6. DCR was observed in 13 patients (52%). By Fisher's exact test, the DCR difference between the two groups was statistically significant (p=0.046). In group A, median PFS was 3.0 months (95%CI:2.1-3.8), compared with 4.0 months (95% CI:3.03-4.97) in group B (p=0.0397 by log-rank test). Epirubicin based chemotherapy and ECOG performance status 0-1 were identified as favorable factors for progression in our cohort of patients. Differences of nonhematologic and hematologic toxicities were not statistically significant between the two groups, and the addition of epirobicin was not associated with cardiac toxicity (p=0.446). Conclusion: Our study demonstrates that epirubicin-based chemotherapy is effective and well tolerated, and is superior to chemotherapy without epirubicin regarding efficacy. Therefore it is recommended that epirubicin-based chemotherapy should be considered as first line for patients with advanced STS.

Effect of Peripheral Blood CD4 + CD25 + Regulatory T Cell on Postoperative Immunotherapy for Patients with Renal Carcinoma

“…Even if radical resection therapy is implemented, there are still relatively high proportion of patients with post-operative metastasis or recurrence. Therefore, comprehensive therapy is of great significance to improving the prognosis of patients with renal and other sites of cancer Liu et al, 2014;Li et al, 2015;Ji et al, 2014;Cui et al, 2015;Cao et al, 2014). Renal carcinoma has relatively poor sensitivity to conventional chemotherapy, radiotherapy and hormone therapy.…”

Computed Tomography Manifestations of Histologic Subtypes of Retroperitoneal Liposarcoma

“…The combination of CT to RT was attempted with the aim to improve the sensitivity of these tumours to RT and provide a systemic coverage as well (Tierney et al, 1997;Pervaiz et al, 2008;Woll et al, 2012;El-Bared et al, 2014). To compare the safety and efficacy of chemotherapy in patients with STS, Cao et al demonstrates that epirubicin-based chemotherapy is effective and well tolerated and Kaya et al suggests that the combination of gemcitabine plus docetaxel is an active and tolerable regimen as a second line therapy (Kaya et al, 2012;Cao et al, 2013). Endostar combined with chemotherapy resulted in a higher disease control rate and longer progression-free survival (Zhang et al, 2013).…”

A Clinical Study on Juheli (Recombinant Human Interleukin - 11) in the Second Prevention of Chemotherapy Induced Thrombocytopenia

“…After TP and PTP were attempted, safety and effectiveness were evaluated. We have enough experience in conducting medical researches, and have published some cancer related results elsewhere Cao et al, 2014;Cui et al, 2014;Ji et al, 2014;Lu et al, 2014;Qian et al, Tian et al, 2014;Wu et al, 2014;Cui et al, 2015;Li et al, 2015;Qian et al, 2015;Shen et al, 2015;Shi et al, 2015;Sun et al, 2015;Wang et al, 2015;Yang et al, 2015;Zhou et al, 2015) …”